Learn about an ongoing study which Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to:

• Identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection.
• Assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection
• Determine utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.